Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | ASH 2020: CAR-T updates to look out for

Tara Gregory • 23 Nov 2020
ASH 2020
General CAR-T Ciltacabtagene autoleucel Orvacabtagene autoleucel

Tara Gregory, MD, Colorado Blood Cancer Institute, Denver, CO, shares the updates in the CAR-T and cellular therapy field that she is looking forward to at ASH 2020. This includes long-term follow-up results from novel CAR-T therapies such as orvacabtagene autoleucel and ciltacabtagene autoleucel, as well as presentations looking at bispecific CAR-Ts. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Tara Gregory

3:35
Phase I/II trial of P-BCMA-101 CAR-T cell therapy in R/R myeloma
Tara Gregory • 23 Nov 2020

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals